Cycloastragenol vs Epitalon

Cycloastragenol wins for oral convenience, solid human data, stack integration, and ongoing low-effort protocols that can be run for months at a time. Its mechanism is more broadly replicated in Western literature and it's widely available from reputable suppliers.

Epitalon wins for pulsed 'reset' protocols (10–20 days on, annual or semi-annual recurrence), dual hit on telomerase and sleep/circadian optimization, and side-effect profile (peptides rarely interact with small-molecule pathways, and it's considered clean except with active malignancy). Fits well where a user wants both telomerase support and sleep normalization, accepts the research group caveat, and is comfortable reconstituting peptides.

Pick Cycloastragenol if:

• Oral administration and seamless stack integration are top priority (no injection or reconstitution requirement)
• Year-round telomerase support is the goal (continuous or long-term cycles)
• Documented human data and supplier transparency matter (easier sourcing, verified brands)
• On-cycle antioxidant and stem-cell support is needed (oxidative stress from AAS, GH, or other stressors)
• Preference is for a protocol measurable via bloodwork, not subjective felt effects

Pick Epitalon if:

• Interest lies in periodic 'service interval' pulses (10–20 day annual or biannual cycles)
• Dual interest in telomerase activity and sleep optimization (circadian rhythm, melatonin)
• Peptide protocols are already routine and SubQ administration is not a barrier
• Willingness to rely on strong but narrower research (most mechanistic data from Khavinson's team)
• Highly sensitive to small-molecule interactions or seeking especially clean side-effect profile